Recently, our company's 100mg aspirin enteric coated tablets have passed the drug consistency evaluation, and the National Medical Products Administration has now released the delivery information of the drug approval certificate.
In addition to the 300mg aspirin enteric coated tablets of Daoqun, which have already been evaluated as early as June 2023, our company now has two aspirin drugs approved for sale on the market.
01 Annual sales exceed 3.2 billion yuan, meeting the threshold for being selected for centralized procurement
Aspirin enteric coated tablets are a commonly used drug for the treatment and prevention of thrombosis. Currently, they have not been included in the national centralized procurement. In the domestic market, there are about 10 companies, including our company, that have been evaluated. In addition, 10 companies including Renhe Yikang have submitted imitation applications for aspirin enteric coated tablets, all of which are currently under review and approval. It can be said that aspirin enteric coated tablets have already reached the threshold for being shortlisted for centralized procurement.
At present, there are over 200 domestic enterprises that have obtained approval for the production of aspirin enteric coated tablets, and Bayer actually occupies a dominant position in the domestic aspirin market. According to data from Zhongkang Kaisi, in recent years, the sales revenue of aspirin enteric coated tablets in national level hospitals has exceeded 1 billion yuan. Among them, the sales of grade hospitals in 2022 were 1.538 billion yuan, with Bayer occupying 95.79% of the market share; In 2022, retail channel sales amounted to 1.685 billion yuan, with Bayer holding a 70% market share; In 2022, the sales revenue of grade hospitals and retail markets exceeded 3.2 billion.
阿司匹林肠溶片全国等级医院销售情况
来源：中康开思系统
Source: Zhongkang Kaisi System
Since Hofmann's first successful preparation in 1897, aspirin has been developed for over a hundred years and is known as one of the three classic drugs in the history of medicine. It is widely recognized as the most widely used antipyretic, analgesic, and anti-inflammatory drug in the world today. However, the highly challenging production process and stability of aspirin enteric coated tablets have once deterred many pharmaceutical companies from pursuing their goals. Since the implementation of consistency evaluation in 2015, it was not until early 2020 that domestic enterprises submitted applications. So far, only three pharmaceutical factories have selected aspirin related drugs in local centralized procurement. To this day, aspirin has not yet been officially included in the centralized procurement list, and this century old "miracle drug" has indeed been on the road to centralized procurement for a long time.
02 There are 330 million domestic cardiovascular disease patients, and the market size of antithrombotic drugs exceeds 30 billion.
With the development of population aging in China, and under the influence of high risk factors such as hypertension, hyperlipidemia, and hyperglycemia, the incidence rate and mortality of thrombotic diseases are on the rise. According to the results of the third national mortality survey, cerebrovascular disease accounts for 22.45% of all deaths in China, with 2.5 million new cases of stroke occurring annually. According to the data released by the National Cardiovascular Disease Center of China in the "China Cardiovascular Health and Disease Report 2022", there are currently about 330 million cardiovascular disease patients in China, and the market size of antithrombotic drugs exceeds 30 billion yuan. Aspirin enteric coated tablets, as a commonly used medication for middle-aged and elderly people, are widely used in clinical practice and play an important role in the treatment and prevention of cardiovascular and cerebrovascular diseases.
Previously, there were media reports that there were significant differences in the bioequivalence of aspirin enteric coated tablets between those that passed consistency evaluation and those that did not. At present, aspirin has shown its research value in multiple fields such as anti-cancer, hypoglycemic, anti-aging, and Alzheimer's disease. The analysis data of the current situation of the aspirin industry shows that, in the global research pipeline of aspirin, traditional fields such as cardio cerebrovascular diseases, pain and thrombosis are still the mainstream of research and development, but new directions such as aspirin, lung cancer and type 2 diabetes are also emerging.
The launch of Daoqun aspirin enteric coated tablets will help accelerate the centralized procurement process of this drug, enhance the competitiveness of domestic drugs in the chronic disease market for middle-aged and elderly people, and provide more medication choices for domestic cardiovascular and cerebrovascular drug consumers. In the future, Daoqun Group will continue to uphold the concept of supporting healthcare and safeguarding health, launch more independently developed products into the pharmaceutical market, strive to promote the development of high-quality domestic drugs, and make more contributions to the development of the medical industry.
The relevant content and some images are from the internet. If there is any infringement, please contact us for deletion